A Serum‐Stable Antimicrobial Peptide‐Based Delivery Platform for Selective Treatment of Nontargetable and Chemoresistant Tumors
Advanced Science · 2025
DOI: 10.1002/advs.202504710 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Tianxing Liu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Natural Drug Discovery Group, School of Pharmacy, Queen's University Belfast, Belfast, Northern Ireland, BT71NN, UK. Hauptthemen laut MEDLINE: Antimicrobial Peptides, Drug Resistance, Neoplasm, Drug Delivery Systems, Antineoplastic Agents. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Antibody–drug conjugates (ADCs) have transformed cancer therapy but remain limited by their dependence on internalizing antigens, poor applicability to untargetable tumors, and susceptibility to drug resistance. Therefore, a modular antimicrobial‐peptide (AMP)‐based therapeutic system centered on a rationally designed conjugate, 270, is presented, which integrates three optimized components: a selectivity‐enhanced AMP core via a membrane affinity reconstruction strategy, a conformation‐driven polyethylene glycolylated blocker to minimize off‐target effects, and an N‐terminal cap to improve stability in human serum. By targeting nonendocytic membrane surface receptors via small‐molecule ligands, conjugate 270 exhibits potent and selective cytotoxicity against target tumor cells, effectively eliminating the majority of tumor cells within a few hours. Meanwhile, it exhibits high serum stability, minimal hemolysis, and negligible cytotoxicity toward normal cells at therapeutic concentrations. Mechanistic studies confirm ligand‐dependent membrane localization, rapid depolarization, and disruption, along with mitochondrial dysfunction. Moreover, it demonstrates significant therapeutic efficacy against four cell lines resistant to conventional chemotherapeutic agents. While additional in vivo validation is warranted, this work lays the foundation for a flexible AMP‐based approach to address untargetable and drug‐resistant cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Natural Drug Discovery Group, School of Pharmacy, Queen's University Belfast, Belfast, Northern Ireland, BT71NN, UK.
- AG Systematik und Evolutionsbiologie, IBU-Faculty V, Carl von Ossietzky University Oldenburg, 26111, Oldenburg, Germany.
- College of Chemistry and Chemical Engineering, Engineering Research Center of Dairy Quality and Safety Control Technology, Ministry of Education, Inner Mongolia University, 235 Daxue West Road, Hohhot, 010021, P. R. Chi…
ORCID-Profile: Xiaoling Chen
Zitieren
APA
Liu, T., Ke, L., Sun, R., Chen, X., Zhou, M., Bininda-Emond, O. R. P., Ma, C., Jiang, Y., Wang, T., Shaw, C., Wang, L., Chen, T., & Dong, A. (2025). A Serum‐Stable Antimicrobial Peptide‐Based Delivery Platform for Selective Treatment of Nontargetable and Chemoresistant Tumors. Advanced Science. https://doi.org/10.1002/advs.202504710
Vancouver
Liu T, Ke L, Sun R, Chen X, Zhou M, Bininda-Emond ORP, et al. A Serum‐Stable Antimicrobial Peptide‐Based Delivery Platform for Selective Treatment of Nontargetable and Chemoresistant Tumors. Advanced Science. 2025. doi:10.1002/advs.202504710
BibTeX
@article{Liu2025,
author = {Liu, Tianxing and Ke, Lingyu and Sun, Ruize and Chen, Xiaoling and Zhou, Mei and Bininda-Emond, Olaf R P and Ma, Chengbang and Jiang, Yangyang and Wang, Tao and Shaw, Chris and Wang, Lei and Chen, Tianbao and Dong, Alideertu},
title = {A Serum‐Stable Antimicrobial Peptide‐Based Delivery Platform for Selective Treatment of Nontargetable and Chemoresistant Tumors},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202504710}
}
EUVIMED